Alector's Progress in Neurodegenerative Therapies Drives Stock Uptick

Alector shares are trading higher after the company reported positive developments in its pivotal INFRONT-3 Phase 3 trial for FTD-GRN and highlighted its strong financial position with $307.3 million in cash.